TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03092817
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
Study: NCT00788242
Drug: Glucose-insulin-potassium
Normalized name: glucose / potassium chloride
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
Study: NCT03889145
Drug: Telmisartan 80mg
Normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 80mg
Study: NCT03889145
Drug: Amlodipine10mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 10mg
Study: NCT03889145
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25mg
Study: NCT01976572
Drug: colestilan
Normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01976572
Drug: candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02413281
Drug: ALKS 5461
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets, single administration
Study: NCT02413281
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sublingual tablets, single administration
Study: NCT04155203
Drug: Mupirocin Calcium
Normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mupirocin cream
Study: NCT04155203
Drug: Mupirocin Calcium
Normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference mupirocin cream
Study: NCT01755377
Drug: Benznidazole
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02592876
Drug: denintuzumab mafodotin
Normalized name: Denintuzumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
Study: NCT02592876
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles
Study: NCT02592876
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
Study: NCT02592876
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
Study: NCT02592876
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
Study: NCT03551691
Drug: Omeprazole 20mg Capsule
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 20mg daily for 28 days
Study: NCT03567629
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
Study: NCT03567629
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
Study: NCT00994175
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003072
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003072
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003072
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01306175
Drug: Digoxin plus BI 10773
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
Study: NCT01306175
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin 0.5 mg as single dose
Study: NCT02136498
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard 12 week course of varenicline, provided in both arms
Study: NCT00368108
Drug: 2 mg perampanel
Normalized name: perampanel 2 MG
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg perampanel
Study: NCT00319800
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00319800
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00368108
Drug: 4 mg perampanel
Normalized name: perampanel 4 MG
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg perampanel
Study: NCT02737826
Drug: Buprenorphine Initiation - Phase I
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
Study: NCT02737826
Drug: Gabapentin + Buprenorphine - Phase II
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
Study: NCT02737826
Drug: Placebo + Buprenorphine - Phase II
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
Study: NCT02737826
Drug: Buprenorphine taper - Phase II
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
Study: NCT02666664
Drug: ETC-1002
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Study: NCT00551850
Drug: AV-412
Normalized name: AV-412
DrugBank: AV-412 (DB06021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
Study: NCT00720564
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00720564
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01122875
Drug: MFGR1877S
Normalized name: MFGR1877S
DrugBank: Vofatamab (DB14781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT02432664
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
Study: NCT01425632
Drug: TAU-284
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU-284 Low
Study: NCT01425632
Drug: TAU-284
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU-284 High
Study: NCT01109511
Drug: naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01109511
Drug: oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03364439
Drug: Treatment plan
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
Study: NCT00919451
Drug: ciclosporin
Normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
Study: NCT02539849
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00129935
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00129935
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02047162
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03514615
Drug: Active gel
Normalized name: Activated Charcoal
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The incision site on one arm will be dosed with the active gel.
Study: NCT01145989
Drug: AT9283
Normalized name: AT9283
DrugBank: AT9283 (DB05169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
Study: NCT02328118
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
Study: NCT02328118
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
Study: NCT00803192
Drug: Famotidine Tablets, 40 mg
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00214253
Drug: Thiazolidinedione
Normalized name: Thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
Study: NCT03680339
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Study: NCT03680339
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 IU of oxytocin with fetal delivery
Study: NCT04115072
Drug: Praziquantel 600Mg Oral Tablet x 5
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five doses of Praziquantel 40 mg/kg
Study: NCT04115072
Drug: Praziquantel 600Mg Oral Tablet x 1
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Praziquantel 40 mg/kg
Study: NCT00258739
Drug: Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
Normalized name: Docetaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
Study: NCT02797522
Drug: ARC-521 Injection
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02797522
Drug: antihistamine
Normalized name: Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
Study: NCT02797522
Drug: entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take entecavir OR tenofovir daily throughout the study.
Study: NCT02797522
Drug: tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants take entecavir OR tenofovir daily throughout the study.
Study: NCT04398329
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl, 50 mg
Study: NCT02710331
Drug: Active Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg capsule of Dronabinol will be administered orally.
Study: NCT03142854
Drug: Polyethylene Glycol (PEG)
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
Study: NCT03142854
Drug: Polyethylene Glycol (PEG)
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
Study: NCT00551330
Drug: Vicriviroc
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of vicriviroc 30 mg once daily
Study: NCT02330094
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.
Study: NCT03487198
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brexpiprazole 2-3mg/day
Study: NCT00999505
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine 200mg twice a day over 12 weeks
Study: NCT03575637
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
Study: NCT04645524
Drug: AD182
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule administered before bed
Study: NCT04645524
Drug: AD504
Normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral capsule administered before bed
Study: NCT00363896
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
Study: NCT00275522
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00703339
Drug: Treprostinil sodium for inhalation
Normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~* Cohort 1: dosed at 3 breaths (18 mcg)~* Cohort 2: dosed at 6 breaths (36 mcg)~* Cohort 3: dosed at 9 breaths (54 mcg)~* Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events.
Study: NCT01052610
Drug: sublingual house dust mites allergen extract
Normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staloral 300 IR, Stallergenes, France
Study: NCT02096042
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT01907867
Drug: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Normalized name: eslicarbazepine
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00569114
Drug: TG01
Normalized name: TG01 vaccine
DrugBank: TG01 vaccine (DB17123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
Study: NCT01886287
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide LAR as outlined in Treatment Arm.
Study: NCT02096042
Drug: 5-Azacytidine
Normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
Study: NCT00828906
Drug: DuoTrav
Normalized name: TRAVOPROST COMPONENT OF DUOTRAV
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DuoTrav Eye Drops
Study: NCT01168063
Drug: Molecular detection of antibiotic resistance
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
Study: NCT02028325
Drug: Fluorescein Sodium
Normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
Study: NCT01078961
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously on days 1, 8 and 15 of each 28 day cycle
Study: NCT01078961
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg taken orally twice a day
Study: NCT01167452
Drug: Sulfamethoxazole/trimethoprim
Normalized name: SULFAMETHOXAZOLE/TRIMETHOPRIM
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
Study: NCT00081575
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003877
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003877
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003877
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00532207
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous 20 micrograms
Study: NCT00305838
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02771379
Drug: Idebenone
Normalized name: Idebenone
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
Study: NCT01261000
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegvisomant used as indicated